Pharvaris’s Phase III HAE Data Position Deucrictibant For 2026 NDA Filing

 
• By Joseph Haas
  
angioedema word cube with background
Pharvaris's Phase III data has the firm ready to file deucrictibant for FDA approval • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business